Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mettler-Toledo International's Debt-to-EBITDA or its related term are showing as below:
FRA:MTO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.34 Med: 1.56 Max: 1.78
Current: 1.78
During the past 13 years, the highest Debt-to-EBITDA Ratio of Mettler-Toledo International was 1.78. The lowest was 1.34. And the median was 1.56.
FRA:MTO's Debt-to-EBITDA is ranked better than 56.25% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.29
vs FRA:MTO: 1.78
Mettler-Toledo International (FRA:MTO) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mettler-Toledo International Debt-to-EBITDA Related Terms
Mettler-Toledo International Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MTO vs ILMN, DGX, LH: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Mettler-Toledo International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mettler-Toledo International Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mettler-Toledo International's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mettler-Toledo International's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Mettler-Toledo International (FRA:MTO) has a Debt-to-EBITDA of 2.15 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mettler-Toledo International. This is 38% above median its historical median of 1.56. Over the past decade, Mettler-Toledo International's Debt-to-EBITDA has ranged from 1.34 to 1.78. According to the industry distribution chart, Mettler-Toledo International ranks #49 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 43.7%.
Is Mettler-Toledo International's Debt-to-EBITDA too high?
Mettler-Toledo International's current Debt-to-EBITDA of 2.15 is 38% above median its 10-year median of 1.56. Over the past 10 years, this metric has ranged from a low of 1.34 to a high of 1.78. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.29. Mettler-Toledo International's value of 2.15 is 6.1% below this industry median. Based on the distribution chart, Mettler-Toledo International ranks #49 out of 112 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Mettler-Toledo International has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Mettler-Toledo International's Debt-to-EBITDA compare to ILMN and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Mettler-Toledo International ranks #49 out of 112 companies for Debt-to-EBITDA. This puts Mettler-Toledo International in the upper half of its industry. The industry median Debt-to-EBITDA is 2.29. Mettler-Toledo International's value of 2.15 is 6.1% below this benchmark. Historically, Mettler-Toledo International's own Debt-to-EBITDA has ranged from 1.34 to 1.78 over the past decade. While the company's 10-year median is 1.56 vs. the industry median of 2.29, Mettler-Toledo International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.29, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mettler-Toledo International's current Debt-to-EBITDA of 2.15 is 6.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mettler-Toledo International. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mettler-Toledo International's current Debt-to-EBITDA is 2.15, which is 38% above median its own 10-year median of 1.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mettler-Toledo International stock overvalued right now?
Mettler-Toledo International (FRA:MTO) has a current Debt-to-EBITDA of 2.15. The stock's GF Value™ is €1,287.55, compared to a current price of €1,141.00 — trading 11.4% below its estimated fair value. The current Debt-to-EBITDA is 2.15, which is 38% above median its 10-year median of 1.56 and 6.1% below the Medical Diagnostics & Research industry median of 2.29. Mettler-Toledo International's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mettler-Toledo International (FRA:MTO), the current Debt-to-EBITDA is 2.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mettler-Toledo International (FRA:MTO) Overvalued in 2026?
Based on GuruFocus' analysis, Mettler-Toledo International stock appears to be undervalued.
The current stock price of €1,141.00 is trading 11.4% below its estimated GF Value™ of €1,287.55.
Key valuation signals for FRA:MTO:
Debt-to-EBITDA: 2.15 (38% above median its 10-year median of 1.56)
GF Value™: €1,287.55 vs. price of €1,141.00 (11.4% below fair value)
Industry Position: 6.1% below the Medical Diagnostics & Research median (#49 of 112)
No single metric tells the full story. See the FRA:MTO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
92GF Score
Get the complete analysis for FRA:MTO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MTO has been successfully added to your 
